<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110103005536N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-09-09</date_registration>
      <primary_sponsor>Army University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effects of melatonin and gabapentin on shivering after knee surgery with spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of two drugs melatonin and gabapentin on shivering after knee surgery with spinal anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/85421</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization using black and white cards.patients are divided into two intervention and control groups. scince the sampling is conveneince or available the first patient who visits is randomly assighed to the melatonin group(if shivering occurs ) by receiving a white card and the next pateint who receives a black card is assighed to the gabapentin group(if shivering occurs), Blinding description: The study is conducted in adouble blinded manner; in this way, the person who performs the statistical analysis and records the necessary variables in each patient, the physician performing the procedure, and the patients themselves are unaware of the type of medication prescribed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Shivering after surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: For group A, melatonin is administered as a single dose of 5 mg orally with 50 cc of water one hour before the operation. Then, after entering the operating room, for spinal anesthesia, they first receive 10 ml/kg of preloaded Ringer's serum fluid, which is kept at 22°C in the operating room, and then they are placed in a sitting position with a 25-gauge spinal needle and injected with 3 injections of 0.5% bupivacaine. Intervention 2: Intervention group: For group B, Gabapentin is administered as a single dose of 5 mg orally with 50 cc of water one hour before the operation. Then, after entering the operating room, for spinal anesthesia, they first receive 10 ml/kg of preloaded Ringer's serum fluid, which is kept at 22°C in the operating room, and then they are placed in a sitting position with a 25-gauge spinal needle and injected with 3 injections of 0.5% bupivacaine.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All research sata can be shared after unidentifying individuals

When:
Start the access period after printing the results

To whom:
All researchers in the field of anesthesia and only by mentioning the source

Conditions:
It can be used only for therapeutic and research purposes and by mentioning the source

Where to obtain:
Dr. Mohammadreza Rafiei

How to obtain:
Send a request email to Dr. Rafiei and receive the data if the user approves

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohamadreza Rafiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Etemadzadeh street. West fatemi</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 8802 8933</telephone>
        <email>mo_rafiei@armyums.ac.ir</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohamadreza Rafiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Etemadzadeh street. West fatemi</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 8802 8933</telephone>
        <email>mo_rafiei@armyums.ac.ir</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients that are 20-60 years old
Patients with (II, I) ASA
No history of taking antidepressants with catecholamine or serotonin reuptake mechanisms (15, 16, 18)
Completion of informed consent by the patient (after full explanation about the safety and health of the various stages of the plan and obtaining informed consent)</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Infusion of blood and its cold products during surgery
Patient or project manager's awareness of the type of medication prescribed
Dissatisfaction of the patient or companions for any reason during the implementation of the plan</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: For group A, melatonin is administered as a single dose of 5 mg orally with 50 cc of water one hour before the operation. Then, after entering the operating room, for spinal anesthesia, they first receive 10 ml/kg of preloaded Ringer's serum fluid, which is kept at 22°C in the operating room, and then they are placed in a sitting position with a 25-gauge spinal needle and injected with 3 injections of 0.5% bupivacaine.</i_keyword>
      <i_keyword>Intervention group: For group B, Gabapentin is administered as a single dose of 5 mg orally with 50 cc of water one hour before the operation. Then, after entering the operating room, for spinal anesthesia, they first receive 10 ml/kg of preloaded Ringer's serum fluid, which is kept at 22°C in the operating room, and then they are placed in a sitting position with a 25-gauge spinal needle and injected with 3 injections of 0.5% bupivacaine.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Shivering. Timepoint: Immediately after surgery until discharge from recovery. Method of measurement: According to the four criteria for grading postoperative tremor (table 1 mentioned in the proposal).</prim_outcome>
      <prim_outcome>Nausea and vomiting. Timepoint: Immediately after surgery until discharge from recovery. Method of measurement: By observing and assessing clinical symptoms and asking the patient questions.</prim_outcome>
      <prim_outcome>Sedation. Timepoint: Immediately after surgery until discharge from recovery. Method of measurement: Any and all degrees of unresponsiveness to auditory and tactile stimuli According to the table grading of sedation(Table 2 mentioned in the proposal).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Army University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-07-30</approval_date>
        <contact_name>Research Ethics Committee of AJA University of Medical Sciences</contact_name>
        <contact_address>Etemadzadeh St. Fatemi St. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
